Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $4.0 million.

  • Monte Rosa Therapeutics' Capital Expenditures rose 63.16% to $651,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 25.08%. This contributed to the annual value of $4.0 million for FY2024, which is 79.06% down from last year.
  • Monte Rosa Therapeutics' Capital Expenditures amounted to $4.0 million in FY2024, which was down 79.06% from $19.0 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Capital Expenditures high stood at $19.0 million for FY2023, and its period low was $3.4 million during FY2020.
  • Over the past 3 years, Monte Rosa Therapeutics' median Capital Expenditures value was $12.9 million (recorded in 2022), while the average stood at $12.0 million.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Capital Expenditures soared by 187.16% in 2021 and then slumped by 79.06% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Capital Expenditures stood at $3.4 million in 2020, then surged by 187.16% to $9.7 million in 2021, then spiked by 32.67% to $12.9 million in 2022, then spiked by 47.48% to $19.0 million in 2023, then crashed by 79.06% to $4.0 million in 2024.